Second cancers in patients with chronic lymphocytic leukemia who received frontline fludarabine, cyclophosphamide and rituximab therapy: distribution and clinical outcomes-Reference-Cited by-同舟云学术

Second cancers in patients with chronic lymphocytic leukemia who received frontline fludarabine, cyclophosphamide and rituximab therapy: distribution and clinical outcomes

Published:2014-11-19 Issue:6 Volume:56 Page:1643-1650
ISSN:1042-8194
Container-title:Leukemia & Lymphoma
language:en
Short-container-title:Leukemia & Lymphoma

Author:

Benjamini Ohad,Jain Preetesh,Trinh Long,Qiao Wei,Strom Sara S.,Lerner Susan,Wang Xuemei,Burger Jan,Ferrajoli Alessandra,Kantarjian Hagop,O'Brien Susan,Wierda William,Estrov Zeev,Keating Michael

Publisher

Informa UK Limited

Subject

Cancer Research,Oncology,Hematology

Link

http://www.tandfonline.com/doi/pdf/10.3109/10428194.2014.957203

Reference59 articles.

1. Subsequent Neoplasia in Chronic Lymphocytic Leukemia

2. Other Malignancies in Chronic Lymphocytic Leukemia/Small Lymphocytic Lymphoma

3. Increased risk of second malignancies in chronic lymphocytic leukaemia patients as compared with follicular lymphoma patients: a Canadian population-based study

4. Chlorambucil in Indolent Chronic Lymphocytic Leukemia

5. Primary Malignant Neoplasms Associated with Chronic Lymphocytic Leukemia

Cited by 129 articles. 订阅此论文施引文献订阅此论文施引文献，注册后可以免费订阅5篇论文的施引文献，订阅后可以查看论文全部施引文献

1. ESMO Clinical Practice Guideline interim update on new targeted therapies in the first line and at relapse of chronic lymphocytic leukaemia;Annals of Oncology;2024-09

2. Chronic lymphocytic leukaemia;The Lancet;2024-08

3. Subsequent Malignancies After CD19-Targeted Chimeric Antigen Receptor T Cells in Patients With Lymphoma;Transplantation and Cellular Therapy;2024-07

4. Chronic Lymphocytic Leukemia: Management of Adverse Events in the Era of Targeted Agents;Cancers;2024-05-24

5. Fludarabine, cyclophosphamide, and rituximab as first‐line treatment in patients with chronic lymphocytic leukemia: A long‐term analysis of the German CLL Study Group (GCLLSG) registry;European Journal of Haematology;2024-05